Janssen Pharmaceutical K.K. clinical trials

A country office of Johnson & Johnson

The registry lists 126 studies whose lead sponsor is Janssen Pharmaceutical K.K.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 7, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 126. List all 126 → · All Johnson & Johnson studies →

• A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseCompletedNCT04397263Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisActive, not recruitingNCT06295692Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland CarcinomaActive, not recruitingNCT04325828Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder CancerActive, not recruitingNCT05567185Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Teclistamab in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT04696809Phase 1/2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial HypertensionCompletedNCT05167825Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Bedaquiline Administered as Part of a Treatment Regimen With Clarithromycin and Ethambutol in Adult Patients With Treatment-refractory Mycobacterium Avium Complex-lung Disease (MAC-LD)CompletedNCT04630145Phase 2/3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in JapanCompletedNCT04459507

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in JapanCompletedNCT04034095

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT04773522Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-75220795 in Japanese ParticipantsTerminatedNCT05039710Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Guselkumab in Participants With Systemic SclerosisCompletedNCT04683029Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)CompletedNCT04062448Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese ParticipantsTerminatedNCT05242432Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care TreatmentsTerminatedNCT03981744Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)TerminatedNCT04882072Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant DepressionCompletedNCT02918318Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-40411813 in Healthy Japanese Male ParticipantsCompletedNCT04677530Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-61393215 in Healthy Japanese Male ParticipantsCompletedNCT04713930Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Symptom Improvement of Ulcerative Colitis After an Induction Dose of Ustekinumab in Japanese Clinical PracticeCompletedNCT04963725

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-67953964 in Healthy Japanese Adult Male ParticipantsCompletedNCT04791332Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid CancersCompletedNCT03547037Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-63733657 in Healthy Japanese ParticipantsCompletedNCT03689153Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• An Observational Study of Japanese Participants With X-linked Retinitis PigmentosaCompletedNCT04868916

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Macitentan, in Healthy Japanese Male ParticipantsCompletedNCT04500808Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Evaluate the Pharmacokinetics (PK) of Darunavir (DRV) and Cobicistat (COBI) After a Single Oral Administration of Darunavir/Cobicistat Fixed-Dose Combination in Healthy Japanese Adult ParticipantsCompletedNCT03123848Phase 4

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• An Efficacy and Safety of Guselkumab in Participants With Palmoplantar PustulosisCompletedNCT02641730Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)CompletedNCT03474679Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell TransplantationCompletedNCT02918331Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Assess the Nicotine Pharmacokinetics, Tolerability and Safety With a New Oral Nicotine Replacement Product in Healthy Japanese SmokersCompletedNCT03398876Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian ParticipantsTerminatedNCT03618160Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and OlderCompletedNCT04354480Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male ParticipantsCompletedNCT03002025Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer Participants Who Responded Poorly to the First-line Combined Androgen Blockade TherapyCompletedNCT02405858Phase 4

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-64530440 in Healthy Japanese Male ParticipantsTerminatedNCT03915886Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)CompletedNCT02365623Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-77242113 in Healthy Japanese and Chinese ParticipantsCompletedNCT05062200Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-75105186 in Healthy Japanese and Chinese ParticipantsWithdrawnNCT05159128Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD)WithdrawnNCT02895815Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal CancerTerminatedNCT04945733Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT03242889Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Ad26.COV2.S in Adults (COVID-19)CompletedNCT04509947Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Evaluate the Different Doses of VAC52416 (ExPEC10V) in Japanese AdultsCompletedNCT04306302Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type PsoriasisCompletedNCT02325219Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Safety Study of JNJ-56021927 in Participants With Metastatic Castration-Resistant Prostate CancerCompletedNCT02162836Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT02343744Phase 3

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naiveCompletedNCT02993250Phase 2

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Treatment-naive Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT02556892Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy ParticipantsWithdrawnNCT02015533Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.

• A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT02497378Phase 1

  Sponsor listed in the registry: Janssen Pharmaceutical K.K.